Cure8 research brief
Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed as potential markers of disease activity.
Researchers, clinicians, and adult patients interested in IBD microbiome biomarkers and disease activity monitoring.
This study used 16S and 18S rRNA sequencing of stool from patients with ulcerative colitis (86 in relapse; a subgroup of 42 who achieved remission) to compare bacterial and fungal community composition between relapse and remission phases.
The relapse phase showed higher relative abundance of several conditionally pathogenic/opportunistic bacteria (examples named in the paper include Actinomyces, Corynebacterium, Enterococcus, Enterobacter, Bradyrhizobium, Escherichia/Shigella).
The remission phase more often showed increased proportions of SCFA-producing and symbiotic taxa (examples: Alistipes, Bifidobacterium, Lachnospiraceae NK4A136 group, Ruminococcus bicirculans). Certain fungal genera (Saccharomyces, Malassezia, Cryptococcus vishniacii) had inverse associations with some clinical indicators.
The paper reports correlation analysis linking specific microbial taxa to clinical and endoscopic activity measures and suggests some taxa could be explored as potential markers of disease activity.
The article is presented as an abstract-level research report in the South Russian Journal of Therapeutic Practice; Cure8 has summarized the source abstract and not the full study report.
Findings come from an abstract-level report using stool 16S/18S sequencing and correlation analyses. Associations do not establish causation and need independent validation and assessment of diagnostic performance before clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
The paper links specific gut bacteria, inflammatory cytokines, and two microRNAs with UC activity, which could point toward new diagnostic biomarkers or targets for research into disease mechanisms.
The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and...
